MediWound has secured approval from the US Food and Drug Administration (FDA) for its NexoBrid (anacaulase-bcdb) treatment for eliminating eschar in adults with deep partial-thickness and/or full-thickness thermal burns.

A bromelain-based biological product, NexoBrid features a sterile mixture of proteolytic enzymes, which selectively eliminate burn eschar within four hours without causing harm to surrounding viable tissue.

Vericel has the exclusive license for the commercialisation of NexoBrid in North America.

The FDA approval of NexoBrid enables MediWound to receive a $7.5m milestone payment from Vericel.

The biologics license applications leading to the approval from the regulatory body are backed by a comprehensive set of pre-clinical studies as well as eight clinical studies, including a pivotal Phase 3 US clinical study called DETECT.

The DETECT trial assessed the efficacy and safety of NexoBrid in adult patients with deep partial-thickness or full-thickness thermal burns over 3% to 30% of their total body surface area (TBSA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, the study achieved its primary endpoint of incidence of ≥95% eschar removal compared to gel.

Furthermore, it met all secondary endpoints, including a lower incidence of surgical eschar removal, shorter time to eschar removal and lower blood loss as against surgical and non-surgical standards of care.

MediWound CEO Ofer Gonen said: “We appreciate and thank the burn patients who participated in our trials, the clinical investigators, and our researchers for their commitment and efforts to attain this significant achievement.

“We also thank our partner, BARDA, for their unwavering support since 2015 and our commercial partner, Vericel, who will launch NexoBrid in the US.”

NexoBrid has already secured approval in 43 countries, including Japan, India, countries in the European Union and other international markets.